Turmeric Efficacy for Mobility and Joint Function

Exclusion Criteria

• •Subjects with any clinically significant levels of the safety parameters at screening
• •Pregnant or lactating females, or wishing to become pregnant during the study
• •Subject with joint pain related to some predisposing conditions that have adversely altered the joint tissues often due to a specific cause
• •Subject with Kellgren-Lawrence grade 4 in the tibio-femoral compartment of the target knee
• •Who has clinically apparent tense effusion of the target knee or other joint
• •Who has/had viscosupplementation in any joint including the target knee or other joint within 6 months prior to screening
• •Who has concomitant inflammatory disease or other condition that affects the joints deemed exclusionary by the Principal Investigator (e.g. rheumatoid arthritis, metabolic bone disease, psoriasis, gout, symptomatic chondrocalcinosis and active infection, etc…)
• •Who has symptomatic osteoarthritis of the contralateral knee that is not responsive to paracetamol and requires other therapy
• •Who is taking any treatment/supplementation which may interfere with study conduct and interpretation of study results (4-weeks washout, e.g. glucosamine, chondroitin, corticosteroids) except calcium and vitamin D supplements
• •Who is under any medical condition deemed exclusionary by the Principal Investigator
• •Subject has a history of drug and / or alcohol abuse at the time of enrollment
• •Change of dietary habit within the preceding month
• •Subject with known organic disease, including an inflammatory bowel disease, a benign or malign tumor of intestine or colon and significant systemic disease
• •Subject currently involved in any other clinical trial or having participated in a trial within the preceding 90 days
• •Subject with known allergy to components of the test product
• •Subject has any concurrent medical or psychiatric condition that, in the opinion of the Investigator, would compromise his/her ability to comply with the study requirements
• •History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years
• •Significant cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, or metabolic/endocrine disorders or other disease that would preclude supplement ingestion and/or assessment of safety and the study objectives
• •Current illnesses which could interfere with the study (e.g. prolonged severe diarrhea, regurgitation/severe, difficulty swallowing)
• •Who is taking any anticoagulant or heparin treatment